Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.

Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, Chang JC, Patre M, Strasak A, de Haas SL, Xu J, Garcia-Saenz JA.

Ann Oncol. 2016 Jul;27(7):1249-56. doi: 10.1093/annonc/mdw157. Epub 2016 Apr 6.

PMID:
27052654
2.

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.

Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, Hewson N, Rukazenkov Y, Robertson JF.

J Clin Oncol. 2015 Nov 10;33(32):3781-7. doi: 10.1200/JCO.2015.61.5831. Epub 2015 Sep 14.

3.

Offering informed choice about breast screening.

Forbes LJ, Ramirez AJ; Expert group on Information about Breast Screening.

J Med Screen. 2014 Dec;21(4):194-200. doi: 10.1177/0969141314555350. Epub 2014 Oct 13.

PMID:
25312639
4.

Comparison of mammographic findings after intraoperative radiotherapy or external beam whole breast radiotherapy.

Elsberger B, Romsauerova A, Vinnicombe S, Whelehan P, Brown DC, Dewar JA, Thompson AM, Evans A.

Eur J Surg Oncol. 2014 Feb;40(2):163-7. doi: 10.1016/j.ejso.2013.11.011. Epub 2013 Dec 4.

PMID:
24332581
5.

Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.

Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, Thompson AM.

Br J Cancer. 2014 Feb 4;110(3):565-72. doi: 10.1038/bjc.2013.756. Epub 2013 Dec 3.

6.

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.

Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M; TARGIT trialists' group.

Lancet. 2014 Feb 15;383(9917):603-13. doi: 10.1016/S0140-6736(13)61950-9. Epub 2013 Nov 11. Erratum in: Lancet. 2014 Feb 15;383(9917):602.

7.

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR; START Trialists' Group.

Lancet Oncol. 2013 Oct;14(11):1086-1094. doi: 10.1016/S1470-2045(13)70386-3. Epub 2013 Sep 19.

PMID:
24055415
8.

Beware using secular trends in deaths to judge effectiveness of breast screening.

Brewster DH, Bhatti LA, Thomson CS, Cameron DA, Dewar JA.

BMJ. 2013 Jul 10;347:f4335. doi: 10.1136/bmj.f4335. No abstract available.

PMID:
23842431
9.

The benefits and harms of breast cancer screening: an independent review.

Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M.

Br J Cancer. 2013 Jun 11;108(11):2205-40. doi: 10.1038/bjc.2013.177. Epub 2013 Jun 6. Review. No abstract available.

10.

Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality.

Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C.

Br J Cancer. 2013 Apr 16;108(7):1515-24. doi: 10.1038/bjc.2013.116. Epub 2013 Mar 21.

11.

Independent UK Panel on Breast Cancer Screening replies to Michael Baum.

Marmot M; Independent UK Panel on Breast Cancer Screening, Altman G, Cameron DA, Dewar JA, Thompson SG, Wilcox M.

BMJ. 2013 Feb 13;346:f873. doi: 10.1136/bmj.f873. No abstract available.

PMID:
23407732
12.

The benefits and harms of breast cancer screening: an independent review.

Independent UK Panel on Breast Cancer Screening.

Lancet. 2012 Nov 17;380(9855):1778-86. doi: 10.1016/S0140-6736(12)61611-0. Epub 2012 Oct 30. Review.

PMID:
23117178
13.

Topoisomerase IIα levels and G2 radiosensitivity in T-lymphocytes of women presenting with breast cancer.

Bryant PE, Riches AC, Shovman O, Dewar JA, Adamson DJ.

Mutagenesis. 2012 Nov;27(6):737-41. doi: 10.1093/mutage/ges040. Epub 2012 Aug 30.

PMID:
22935224
14.

CD recording of clinical consultations in the oncology clinic for subsequent patient use.

Adamson DJ, Dewar JA, Adamson GD.

Clin Oncol (R Coll Radiol). 2012 Nov;24(9):e142. doi: 10.1016/j.clon.2012.07.002. Epub 2012 Jul 26. No abstract available.

PMID:
22841440
15.

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.

Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J; BIG 1-98 Collaborative Group; International Breast Cancer Study Group.

Br J Cancer. 2012 May 8;106(10):1618-25. doi: 10.1038/bjc.2012.156. Epub 2012 Apr 24.

16.

A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy.

Fong A, Shafiq J, Saunders C, Thompson AM, Tyldesley S, Olivotto IA, Barton MB, Dewar JA, Jacob S, Ng W, Speers C, Delaney GP.

Breast. 2012 Aug;21(4):570-7. doi: 10.1016/j.breast.2012.02.014. Epub 2012 Mar 16.

PMID:
22425535
17.

A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy.

Fong A, Shafiq J, Saunders C, Thompson A, Tyldesley S, Olivotto IA, Barton MB, Dewar JA, Jacob S, Ng W, Speers C, Delaney GP.

Breast. 2012 Aug;21(4):562-9. doi: 10.1016/j.breast.2012.01.006. Epub 2012 Jan 31.

PMID:
22297168
18.

Importance of long-term follow-up of women receiving adjuvant therapy for breast cancer in the community.

McCowan C, Dewar JA, Thompson AM.

J Clin Oncol. 2011 Sep 1;29(25):3492; author reply 3492; discussion 3492-3. doi: 10.1200/JCO.2011.37.0528. Epub 2011 Jul 18. No abstract available.

PMID:
21768466
19.

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM.

Breast Cancer Res Treat. 2011 Aug;128(3):783-94. doi: 10.1007/s10549-011-1612-1. Epub 2011 Jun 8.

PMID:
21655990
20.

Differential contextual responses of normal human breast epithelium to ionizing radiation in a mouse xenograft model.

Coates PJ, Appleyard MV, Murray K, Ackland C, Gardner J, Brown DC, Adamson DJ, Jordan LB, Purdie CA, Munro AJ, Wright EG, Dewar JA, Thompson AM.

Cancer Res. 2010 Dec 1;70(23):9808-15. doi: 10.1158/0008-5472.CAN-10-1118. Epub 2010 Nov 16.

Supplemental Content

Loading ...
Support Center